Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Atorvastatin and Ezetimibe in Patients with Acute Coronary Syndrome
Author(s): Mohammed Sallam , Hossameldin Hassan , Derek Connolly , et al Added: 8 months ago

Prevention & Chronic Conditions

MI/ACS
Apabetalone: Evidence and Outcomes Related to Cardiovascular Health
Author(s): Yimeng Zhang , Nimai Desai , Derek Connolly Added: 4 months ago

Prevention & Chronic Conditions

CV Disease in Special Populations
William Herrington
Research Area(s) / Expertise: Job title: Professor of Trials and Epidemiology of Kidney Disease
Professor William Herrington is an Honorary Consultant Nephrologist at Oxford Kidney Unit and the Professor of Trials and Epidemiology of Kidney Disease at the Nuffield Department of Population Health, University of Oxford.Prof Herrington earned his MD from the University of Cambridge in 2013, focusing on the impact of lowering LDL cholesterol on stroke in chronic kidney disease.He has previously… View more
Remnant Lipoproteins and ASCVD
Author(s): Mohanad Gabani , Michael D Shapiro , Peter P Toth Added: 1 year ago

Prevention & Chronic Conditions
PCSK9 Inhibition: The Big Step Forward in Lipid Control
Author(s): Rishi Rikhi , Michael D Shapiro Added: 2 years ago

Vascular Disease and Surgery

Prevention & Chronic Conditions
Dr Oliver Weingärtner currently works at University Hospital Jena. As a certified interventional cardiologist and angiologist he has been trained inInternal Medicine, Cardiology, Angiology and Intensive Care MedicineLipidologist (DGFF®) Dr Weingärtner is the current President of the German Society of Lipidology. His research interests focus on cholesterol metabolism and cardiovascular risk. View more
ACC 23: Inflammatory Risk from Statin-Treated Patients
Author(s): Paul M Ridker Added: 2 years ago
ACC.23/WCC - We are joined by Dr Paul Ridker (Brigham and Women’s Hospital, US) to discuss the findings from a collaborative analysis of 31,197 patients to assess inflammatory risk in statin-treated patients. The PROMINENT, REDUCE-IT and STRENGTH trials were each large contemporary trials which implemented guideline-directed medical therapy, the findings of which were pooled in this study. The… View more

Prevention & Chronic Conditions
AHA 23: 3 Trials That Will Change My Practice
Author(s): Purvi Parwani Added: 1 year ago
AHA 23 — Dr Purvi Parwani, cardiologist and multimodality imager, and director of the Women's Heart Clinic at Loma Linda University Health in the US, spotlights three game-changing late-breaking science trials from the AHA Scientific Sessions. Discover the trials anticipated to reshape clinical practices as Dr Parwani shares her insights.Trials discussed in detail include:POP-HT: Cardiac… View more

Guidelines & Statements

Prevention & Chronic Conditions
AHA 24: The BROOKLYN Study
Author(s): Stephen Nicholls Added: 7 months ago
AHA Conference 2024 - BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management.Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745).BROOKLYN is a phase 3,… View more

Prevention & Chronic Conditions
ESC 23: LIBerate-HeFH Study
Author(s): Frederick Raal Added: 1 year ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104). The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in… View more

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions